Tempest Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing that its reconvened special meeting of stockholders, held November 12, 2026, was adjourned again after insufficient votes were cast to approve a proposed amendment to the company's Restated Certificate of Incorporation.

Key Highlights

  • Meeting adjourned again: The November 12, 2026 special meeting was adjourned for the fourth time, following prior adjournments on July 27, August 17, September 15, and October 14, 2026.
  • Quorum was present: A total of 11,052,422 shares, or 74.64% of the 14,806,997 shares outstanding as of the May 28, 2026 record date, were present or represented by proxy.
  • High approval threshold required: The proposal requires the affirmative vote of holders of at least 75% of votes entitled to be cast in any annual election of directors.
  • Next meeting date set: The special meeting will reconvene on December 11, 2026 at 12:00 p.m. Eastern Time via live webcast.
  • Proposal unchanged: According to the filing, no changes have been made to the proposal to be voted on at the reconvened meeting.
  • Proxy solicitor engaged: The company has engaged Sodali & Co. to assist with obtaining adequate votes to achieve the required quorum.

Tempest Therapeutics Special Meeting: Governance Amendment Still Pending

Tempest Therapeutics, a clinical-stage biopharmaceutical company incorporated in Delaware and headquartered in Brisbane, California, reported via NASDAQ:TPST that its special meeting of stockholders was called to order on November 12, 2026 and subsequently adjourned. The meeting was originally convened on July 27, 2026, making the November 12 session the fourth in a series of reconvened gatherings, all aimed at obtaining sufficient stockholder approval for a single governance proposal.

The proposal before stockholders seeks to amend the company's Restated Certificate of Incorporation to replace specified supermajority voting requirements and to permit stockholder action by written consent, in the form attached as Exhibit A to the previously distributed proxy statement. The filing states that the record date for stockholder eligibility remains the close of business on May 28, 2026, and that proxies already submitted will carry over to the December 11, 2026 reconvened meeting unless properly revoked. Stockholders who have already voted and do not wish to change their vote are not required to take any further action, according to the filing.

The filing notes that although a quorum of 74.64% of outstanding shares was present or represented at the November 12 meeting, votes in favor of the proposal were not sufficient to meet the 75% affirmative vote threshold required for approval. The company indicated it decided to adjourn in order to provide stockholders with additional time to vote and to facilitate broader participation. Matthew Angel, President and Chief Executive Officer, signed the filing on November 16, 2026.

What Was Disclosed

Tempest Therapeutics disclosed the outcome of its November 12, 2026 special meeting, the quorum achieved, the vote threshold required, and the scheduling of a further reconvened meeting on December 11, 2026, with no changes to the underlying proposal.